XENE
NASDAQ · Biotechnology
Xenon Pharmaceuticals Inc
$56.44
+0.44 (+0.79%)
Financial Highlights (FY 2026)
Revenue
9.23M
Net Income
-426,077,835
Gross Margin
—
Profit Margin
-4,612.1%
Rev Growth
-7.4%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 64.7% | 64.7% |
| Operating Margin | -4,974.3% | -4,476.8% | -15.1% | -14.3% |
| Profit Margin | -4,612.1% | -4,381.5% | -18.8% | -18.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 9.23M | 9.97M | 1.14B | 960.22M |
| Gross Profit | — | — | 736.80M | 621.33M |
| Operating Income | -459,372,491 | -446,233,396 | -172,342,535 | -137,273,182 |
| Net Income | -426,077,835 | -413,891,043 | -213,860,892 | -175,272,807 |
| Gross Margin | — | — | 64.7% | 64.7% |
| Operating Margin | -4,974.3% | -4,476.8% | -15.1% | -14.3% |
| Profit Margin | -4,612.1% | -4,381.5% | -18.8% | -18.3% |
| Rev Growth | -7.4% | -7.4% | +15.1% | -2.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 531.67M | 483.73M |
| Total Equity | — | — | 1.61B | 1.62B |
| D/E Ratio | — | — | 0.33 | 0.30 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -456,399,004 | -467,975,233 | -248,558,556 | -208,894,236 |
| Free Cash Flow | — | — | -268,893,932 | -239,063,358 |